Reuters logo
BRIEF-European Commission grants marketing authorization for Gilead's Vemlidy (Tenofovir Alafenamide, TAF) for the treatment of chronic hepatitis B virus infection
January 11, 2017 / 12:09 PM / 10 months ago

BRIEF-European Commission grants marketing authorization for Gilead's Vemlidy (Tenofovir Alafenamide, TAF) for the treatment of chronic hepatitis B virus infection

Jan 11 (Reuters) - Gilead Sciences Inc

* European Commission grants marketing authorization for Gilead’s Vemlidy (Tenofovir Alafenamide, TAF) for the treatment of chronic hepatitis B virus infection Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below